Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,321 papers from all fields of science
Search
Sign In
Create Free Account
Carcinoma in situ of esophagus
Known as:
Severe Esophageal Dysplasia
, stage 0 esophageal carcinoma in situ
, Esophageal Carcinoma in situ AJCC v7
Expand
Stage 0 includes: For squamous cell carcinoma: Tis (HGD), N0, M0, G1, GX, Tumor location: Any. For adenocarcinoma: Tis (HGD), N0, M0, G1, GX. Tis…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
18 relations
Benign neoplasm of esophagus
Carcinoma in Situ
Epithelial Cells
Epithelium
Expand
Broader (1)
Esophageal Diseases
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Impact of Wind Generation on Electricity Prices in Day Ahead Market
T. Nguyen
2015
Corpus ID: 107032659
This master thesis aims at understanding the impact of wind on day-ahead-market (DAM) electricity prices using an integrated…
Expand
2010
2010
Clinical outcome of local recurrence cases after endoscopic mucosal resection (EMR) for Japanese Classification stage 0 esophageal cancer.
T. Yoshii
,
S. Ohkawa
2010
Corpus ID: 74036080
4135 Background: Endoscopic mucosal resection (EMR) is minimally invasive. When esophageal cancer (EC) is limited to mucosa…
Expand
2007
2007
Changes of COX-2 and VEGF expressions in esophageal precancerous and cancerous lesions from the patients at high incidence area in Henan province
G. Xing
,
Li Dong Wang
,
+6 authors
Aiqun Wu
2007
Corpus ID: 39251450
Objective. To determine the changes and clinical significance of cyclooxygenase-2 (COX-2) and vascular endothelial growth factor…
Expand
2005
2005
Expression of IL-2, IL-10 in carcinoma cells and tumor infiltrating lymphocytes of esophageal carcinoma in situ
Chen Yi-feng
2005
Corpus ID: 75994586
To explore the immunohistochemical expression of IL-2, IL-10 in carcinoma cells and tumor infiltrating lymphocytes of esophageal…
Expand
Review
2004
Review
2004
Endoscopic survey of esophageal cancer in a high-risk area of China.
Xu-jing Lu
,
Zhi-feng Chen
,
+7 authors
J. Hou
World Journal of Gastroenterology
2004
Corpus ID: 32323600
AIM To characterize the histological types of esophageal and cardiac mucosa by endoscopic survey of a population in a high-risk…
Expand
2003
2003
Expression of CD44v6 and P16 gene in esophageal carcinoma in situ hybridization
N. Pla
2003
Corpus ID: 87244472
Objective To investigate the expression of CD44v6 and P16 gene in esophageal carcinoma tissue and their relationship. Methods…
Expand
2003
2003
Comets C/2002 V6 and C/2002 V7 (SOHO)
D. Hammer
,
K. Cernis
,
R. Matson
,
B. G. Marsden
2003
Corpus ID: 92700726
2001
2001
[Abnormal expression of p53, Ki67 and iNOS in human esophageal carcinoma in situ and pre-malignant lesions].
Y. Jin
,
W. Zhang
,
B. Liu
Zhonghua zhong liu za zhi [Chinese journal of…
2001
Corpus ID: 19749100
OBJECTIVE To investigate alterations in expression of Ki67, p53 and iNOS proteins in esophageal carcinogenesis. METHODS The…
Expand
1998
1998
Evaluation of esophageal cytology using a neural net-based interactive scanning system (the PAPNET system): its possible role in screening for esophageal and gastric carcinoma.
Leopold G. Koss
,
Nora Morgenstern
,
Naveed Tahir-Kheli
,
M. Suhrland
,
Klaus Schreiber
,
Ellen Greenebaum
American Journal of Clinical Pathology
1998
Corpus ID: 35746050
A neural net-based, semiautomated, interactive computerized cell analysis system (The PAPNET system, Neuromedical Systems…
Expand
1988
1988
Second line prevention from esophageal cancer inhibitory therapy to block precancerous lesions
P. Lin
,
Jin-Sheng Zhang
,
+4 authors
R. Gao
1988
Corpus ID: 71582474
In 1983, for the purpose of prevention from esophageal cancer, inhibitory therapy was put on trial in Heshunxiang of Linxian…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE